Unknown

Dataset Information

0

In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity.

ABSTRACT: Ovarian cancer is the second most common gynecological malignancy worldwide. Paclitaxel is particularly important in the therapy of ovarian carcinomas, but the treatment efficacy is counteracted by the development of resistance to chemotherapy. The identification of target molecules that can prevent or control the development of chemoresistance might provide important tools for the management of patients affected by ovarian cancer. Serum- and glucocorticoid-regulated kinase 1 (SGK1) appears to be a key determinant of resistance to chemo- and radiotherapy. Specifically, SGK1 affects paclitaxel sensitivity in RKO colon carcinoma cells by modulating the specificity protein 1 (SP1)-dependent expression of Ran-specific GTPase-activating protein (RANBP1), a member of the GTP-binding nuclear protein Ran (RAN) network that is required for the organization and function of the mitotic spindle. SGK1 inhibition might thus be useful for counteracting the development of paclitaxel resistance. Here, we present in vitro data obtained using ovarian carcinoma cell lines that indicate that the SGK1 inhibitor SI113 inhibits cancer cell proliferation, potentiates the effects of paclitaxel-based chemotherapy, counteracts the development of paclitaxel resistance, and restores paclitaxel sensitivity in paclitaxel-resistant A2780 ovarian cancer cells. The results were corroborated by preclinical studies of xenografts generated in nude mice through the implantation of paclitaxel-resistant human ovarian cancer cells. The SGK1 inhibitor SI113 synergizes with paclitaxel in the treatment of xenografted ovarian cancer cells. Taken together, these data suggest that SGK1 inhibition should be investigated in clinical trials for the treatment of paclitaxel-resistant ovarian cancer.

SUBMITTER: D'Antona L 

PROVIDER: S-EPMC6545392 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity.

D'Antona Lucia L   Dattilo Vincenzo V   Catalogna Giada G   Scumaci Domenica D   Fiumara Claudia Vincenza CV   Musumeci Francesca F   Perrotti Giuseppe G   Schenone Silvia S   Tallerico Rossana R   Spoleti Cristina B CB   Costa Nicola N   Iuliano Rodolfo R   Cuda Giovanni G   Amato Rosario R   Perrotti Nicola N  

Translational oncology 20190601 8

Ovarian cancer is the second most common gynecological malignancy worldwide. Paclitaxel is particularly important in the therapy of ovarian carcinomas, but the treatment efficacy is counteracted by the development of resistance to chemotherapy. The identification of target molecules that can prevent or control the development of chemoresistance might provide important tools for the management of patients affected by ovarian cancer. Serum- and glucocorticoid-regulated kinase 1 (SGK1) appears to b  ...[more]

Similar Datasets

Unknown Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy.
| S-EPMC4741945 | biostudies-literature
Unknown Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.
| S-EPMC8891641 | biostudies-literature
Unknown Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
| S-EPMC4059749 | biostudies-literature
Unknown CHFR and Paclitaxel Sensitivity of Ovarian Cancer.
| S-EPMC8657201 | biostudies-literature
Transcriptomics miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
2014-02-04 | E-GEOD-54665 | biostudies-arrayexpress
Unknown SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells.
| S-EPMC4941283 | biostudies-literature
Unknown miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.
| S-EPMC4650519 | biostudies-literature
Unknown A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
| S-EPMC4775414 | biostudies-literature
Genomics miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
2014-02-04 | GSE54665 | GEO
Unknown Cold Atmospheric Plasma Restores Paclitaxel Sensitivity to Paclitaxel-Resistant Breast Cancer Cells by Reversing Expression of Resistance-Related Genes.
| S-EPMC6966695 | biostudies-literature